Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Vivani Medical (U5P) Stock Price & Analysis

U5P Stock Chart & Stats

€0.94-€0.03(-3.61%)
At close: 5:30 PM GMT+1
EUR 0.975EUR 1EUR 1.025EUR 1.0524 Sep20 Oct
Day’s Range
EUR 0.94 - EUR 0.94
52-Week Range
EUR 0.74 - EUR 1.40
Previous Close
EUR 0.97
Volume
0
Average Volume (3M)
17
Market Cap
EUR 87.74M
Enterprise Value
EUR 105.99M
Total Cash (Recent Filing)
EUR 19.89M
Total Debt (Recent Filing)
EUR 17.86M
Price to Earnings (P/E)
―
Beta
0.68
Next Earnings
Nov 18, 2026 (Est.)
EPS Estimate
-0.08
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Clinical Execution

Completing all 20 participants ahead of schedule demonstrates clinical execution and moves NPM-139 toward top-line readout, an IND filing, and planned Phase 2 work. That progress can strengthen the pipeline’s development value over the next several quarters.

External Validation

Novo Nordisk’s evaluation provides external validation from a major industry participant for both NPM-139 and NanoPortal. While non-exclusive and not a commercialization deal, the relationship may improve credibility and inform future partnering or development decisions.

Strategic Focus

Separating Cortigent through the planned ClearOne transaction could reduce Vivani’s direct neurostimulation spending and sharpen focus on its implant drug-delivery programs. If completed, the reorganization may improve strategic focus and resource allocation.

Bears Say

No Commercial Revenue

The absence of revenue and persistent losses show that Vivani has not yet converted its development programs into commercial output. Until a product reaches market, the company lacks operating leverage and remains dependent on financing to advance its pipeline.

Persistent Cash Burn

Sustained negative operating and free cash flow indicates that core activities consume substantial cash rather than fund themselves. Continued burn can pressure liquidity and force Vivani to seek additional capital before clinical programs generate meaningful commercial cash inflows.

Meaningful Leverage

Debt approaching the level of equity reduces financial flexibility while Vivani is still loss-making and cash-burning. If additional funding is required, existing leverage may increase financing costs or amplify dilution and constrain capital allocation across clinical programs.

Vivani Medical News

U5P FAQ

What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was €0.74 and its highest was €1.40 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is €87.74M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s next earnings report is estimated for Nov 18, 2026 (not yet confirmed), which is in 16 days.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on Aug 13, 2026. The company reported -€0.062 earnings per share for the quarter, beating the consensus estimate of -€0.074 by €0.012.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -0.08.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 90,203,354 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -€0.062 in its last earnings report, beating expectations of -€0.074. Following the earnings report the stock price went down -1.835%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in DE:U5P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology